Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide french series comparing children and adults

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 4, 2013, Pages 554-562

  Fremeaux Bacchi, Véronique ^a   Fakhouri, Fadi ^a   Garnier, Arnaud ^a   Bienaimé, Frank ^a   Dragon Durey, Marie Agnès ^a   Ngo, Stéphanie ^a   Moulin, Bruno ^a   Servais, Aude ^a   Provot, François ^a   Rostaing, Lionel ^a   Burtey, Stéphane ^a   Niaudet, Patrick ^a   Deschênes, Georges ^a   Lebranchu, Yvon ^a   Zuber, Julien ^a   Loirat, Chantal ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; MEMBRANE COFACTOR PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CHROMOSOME ABERRATION; COHORT ANALYSIS; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMPLEMENT SYSTEM PROTEINS; FEMALE; FRANCE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; YOUNG ADULT;

EID: 84876044818     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04760512     Document Type: Article

References (21)

1. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009
2. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, LeQuintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V: Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21: 2180-2187, 2010
3. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes- Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V: Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114: 2837-2845, 2009
4. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S, Hue C, Satchell SC, Mathieson PW, Mousson C, Noel C, Sautes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Lionet A, Fremeaux-Bacchi V: A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119: 4182-4191, 2012
5. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, Deng HW, Goodship TH: The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: Evidence from two independent cohorts. J MedGenet 42: 852- 856, 2005
6. Esparza-Gordillo J, Jorge EG, Garrido CA, Carreras L, López-Trascasa M, Sánchez-Corral P, de Córdoba SR: Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 43: 1769-1775, 2006
7. Ermini L, Goodship TH, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS: Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 49: 640-648, 2012
8. Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P: Characterization of complement factorH-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114: 4261-4271, 2009
9. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844-1859, 2010
10. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31: E1445-E1460, 2010
11. Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, Fehr T, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP: Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 75: 639-647, 2011
12. Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, van Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L: Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 25: 2195-2202, 2010
13. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C; French Society of Pediatric Nephrology: Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18: 2392-2400, 2007
14. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP: Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108: 1267-1279, 2006
15. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs- Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V: Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365: 8-26, 2011
16. Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952, 2008
17. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204: 1249-1256, 2007
18. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F, Rondeau E, Frémeaux-Bacchi V: Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21: 859-867, 2010
19. Zuber J, Quintrec ML, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, F-Bacchi V, Rondeau E, Legendre C, Loirat C; the French Study Group for atypical HUS: Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12: 3337-3354, 2012
20. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8: 643-657, 2012
21. Salant DJ: Targeting complement C5 in atypical hemolytic uremic syndrome. J Am Soc Nephrol 22: 7-9, 2011